Bristol-Myers Squibb Co. inked a collaboration and licensing deal with Jiangsu Hengrui Pharmaceuticals Co. that could be valued at as much as $15.2 billion, as the US drugmaker seeks to leverage China’s efficiency in early development.
www.bloomberg.com
#BristolMyers #Inks #Billion #Licensing #Deal #Hengrui
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui
